| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.71B | 13.97B | 16.08B | 23.38B | 23.20B | 13.11B |
| Gross Profit | 5.59B | 4.88B | 3.50B | 8.39B | 8.57B | 5.39B |
| EBITDA | 2.55B | 2.65B | 3.53B | 6.24B | 6.36B | 3.79B |
| Net Income | 1.52B | 1.58B | 2.05B | 3.26B | 3.68B | 2.38B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 22.52B | 21.46B | 19.63B | 18.75B | 13.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.50B | 3.50B | 3.31B | 3.09B | 515.37M | 173.23M |
| Total Debt | 0.00 | 110.27M | 196.97M | 575.74M | 1.01B | 1.27B |
| Total Liabilities | -20.18B | 2.34B | 2.53B | 2.65B | 5.60B | 4.00B |
| Stockholders Equity | 20.18B | 18.45B | 17.22B | 15.54B | 12.50B | 8.94B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 874.82M | 704.14M | 2.62B | 842.07M | -221.07M |
| Operating Cash Flow | 0.00 | 2.73B | 3.34B | 3.82B | 2.32B | 1.10B |
| Investing Cash Flow | 0.00 | -1.61B | -1.64B | -1.86B | -1.47B | -615.89M |
| Financing Cash Flow | 0.00 | -447.73M | -749.66M | -812.33M | -565.13M | -374.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹35.97B | 26.33 | ― | 0.08% | 15.47% | -1.72% | |
65 Neutral | ₹45.54B | 29.91 | ― | 0.77% | -12.28% | -22.10% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹93.53B | 51.34 | ― | 0.55% | 3.95% | 8.28% | |
56 Neutral | ₹122.24B | 78.69 | ― | 0.07% | 69.32% | 113.55% | |
55 Neutral | ₹38.85B | 115.48 | ― | 0.07% | 11.14% | -11.15% | |
46 Neutral | ₹9.49B | 102.13 | ― | 1.03% | -19.46% | -80.73% |
Balaji Amines Limited has issued a clarification regarding a defamatory article published in the Economic Times, which falsely accused the company of producing pharmaceutical-grade chemicals without a license. The company refutes these claims, stating that they only manufacture technical and food grade Propylene Glycol and have not supplied any pharmaceutical-grade products. Balaji Amines emphasizes their commitment to transparency and compliance with regulations, noting that there is no ongoing investigation by Indian authorities as suggested in the article.
Balaji Amines Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. This certificate confirms that the securities received for dematerialization have been processed, with the depositories’ names updated in the company’s records within the required timeframe, ensuring compliance with regulatory standards.
Balaji Amines Limited conducted its 37th Annual General Meeting (AGM) on August 8, 2025, via video conference, adhering to the guidelines from the Ministry of Corporate Affairs and SEBI. The meeting was chaired by Executive Chairman Mr. Ande Prathap Reddy, with 62 members present. The AGM included the presentation of the company’s audited financial statements for the year ending March 31, 2025, which were accepted without any qualifications or remarks from the auditors. The company provided remote e-voting facilities for shareholders to participate in decision-making, ensuring transparency and compliance with regulatory standards.